Evaluation and selecting indications for the treatment of improving facial morphology by masseteric injection of botulinum toxin type A

Li, Gaofeng; Tan, Jun; Pan, Bo; Bosheng, Zou; Qian, Zhenghong; Liu, Dongping

doi:10.1016/j.bjps.2009.12.019

Cited by 13 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported incidence rate for this complication is around 0.9%‐63.6% . The reduction of mastication force starts around 1‐4 weeks after treatment . According to Ahn et al and Kim et al, patients experienced a 20‐40 percent decrease in mean bite force 2 weeks after treatment compared to pre‐injection values.…”

Section: Resultsmentioning

confidence: 99%

“…According to Park et al, when compared to pre‐injection values at 4 weeks post‐injection, masticatory function decreased by 89.2% (mixing ability index), 12.2% (food intake ability), and 32.2% (visual analog scale), respectively. The bite force will gradually be restored in 3‐8 weeks and usually returns to pre‐injection levels in around 12 weeks . In a MRI evaluation study, muscular atrophy persisted for 4 months after a single treatment and full recovery took sixth months …”

Section: Resultsmentioning

confidence: 99%

“…These complications were grouped together because of their common etiology of localized vascular damage—transient swelling after injection may be caused by the minor rupture of the blood vessels, and bruising is caused by venous or capillary damage during treatment, while hematoma is caused by artery or arteriole puncture without adequate application of pressure. Local swelling is a nonspecific complication of BoNT injections with an incidence rate of around 6.3%‐22.7%, and often recovers in 2 to 3 days . Gaofeng et al reported that local swelling appeared in 5 out of 32 treated patients in the early period after injection and recovered within 1 week.…”

Section: Resultsmentioning

confidence: 99%

“…3,4,8,11,33,34,36 The reported incidence rate for this complication is around 0.9%-63.6%. 11,18,30,33,34,37 The reduction of mastication force starts around 1-4 weeks after treatment. 18,36,[38][39][40][41] tively.…”

Section: Chewing Weaknessmentioning

confidence: 99%

“…Perhaps owing to the low incidence rate, reports on the complications of toxin injections for masseter hypertrophy remain rare or even unobserved in certain studies despite the treatment's popularity. 1,[15][16][17][18][19][20][21][22][23][24][25][26][27] Current literature does not offer comprehensive reviews of the time, prognosis, or recovery process of related complications, and the Cochrane review in 2009 and 2013 reported an insufficient amount of high level evidence to accurately assess the efficacy and safety of toxin injections for masseter hypertrophy. 28,29 A previous report by the authors in 2018 outlined masseter toxin injection complication rates from 2036 treatments, 30 though it was limited in scope to a single clinic.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy

Yeh¹,

Peng²,

Peng³

2018

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Botulinum toxin masseter injections are commonly performed procedures with good results and safety profiles. The majority of complications appeared within 2-4 weeks of injection and disappeared within 12 weeks. Despite the temporary nature of these complications, they often decrease patient satisfaction and confidence, so physicians should familiarize themselves with the regional anatomy and injection safety zones.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Chewing Weaknessmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Literature review of the adverse events associated with botulinum toxin injection for the masseter muscle hypertrophy

Yeh¹,

Peng²,

Peng³

2018

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

Consensus on Current Injectable Treatment Strategies in the Asian Face

Wu¹,

Liew²,

Chan

et al. 2016

Aesth Plast Surg

View full text Add to dashboard Cite

BackgroundThe desire for and use of nonsurgical injectable esthetic facial treatments are increasing in Asia. The structural and anatomical features specific to the Asian face, and differences from Western populations in facial aging, necessitate unique esthetic treatment strategies, but published recommendations and clinical evidence for injectable treatments in Asians are scarce.MethodThe Asian Facial Aesthetics Expert Consensus Group met to discuss current practices and consensus opinions on the cosmetic use of botulinum toxin and hyaluronic acid (HA) fillers, alone and in combination, for facial applications in Southeastern and Eastern Asians. Consensus opinions and statements on treatment aims and current practice were developed following discussions regarding pre-meeting and meeting survey outcomes, peer-reviewed literature, and the experts’ clinical experience.ResultsThe indications and patterns of use of injectable treatments vary among patients of different ages, and among Asian countries. The combination use of botulinum toxin and fillers increases as patients age. Treatment aims in Asians and current practice regarding the use of botulinum toxin and HA fillers in the upper, middle, and lower face of patients aged 18 to >55 years are presented.ConclusionsIn younger Asian patients, addressing proportion and structural features and deficiencies are important to achieve desired esthetic outcomes. In older patients, maintaining facial structure and volume and addressing lines and folds are essential to reduce the appearance of aging. This paper provides guidance on treatment strategies to address the complex esthetic requirements in Asian patients of all ages.Level of Evidence VThis journal requires that the authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

show abstract